Edition:
United Kingdom

ANI Pharmaceuticals Inc (ANIP.OQ)

ANIP.OQ on NASDAQ Stock Exchange Global Market

63.75USD
17 Nov 2017
Change (% chg)

$0.81 (+1.29%)
Prev Close
$62.94
Open
$62.64
Day's High
$64.00
Day's Low
$62.55
Volume
23,585
Avg. Vol
47,856
52-wk High
$65.75
52-wk Low
$42.26

Latest Key Developments (Source: Significant Developments)

ANI Pharmaceuticals Q3 gaap earnings per share $0.40
Thursday, 2 Nov 2017 

Nov 2 (Reuters) - ANI Pharmaceuticals Inc :ANI Pharmaceuticals reports record third quarter and year-to-date 2017 results and narrows full year guidance.Q3 adjusted Non-GAAP earnings per share $1.11.Q3 GAAP earnings per share $0.40.Q3 revenue $48.2 million versus I/B/E/S view $48.1 million.Q3 earnings per share view $0.99 -- Thomson Reuters I/B/E/S.ANI Pharmaceuticals Inc sees ‍for full year 2017 net revenues $181 million to $183 million​.ANI Pharmaceuticals Inc sees ‍for full year 2017 adjusted Non-GAAP diluted earnings per share $3.83 to $4.00​.Q3 earnings per share view $0.99, revenue view $48.1 million -- Thomson Reuters I/B/E/S.FY2017 earnings per share view $3.84, revenue view $182.1 million -- Thomson Reuters I/B/E/S.ANI Pharmaceuticals Inc - ‍ANI intends to request a meeting with fda in Q4 of 2017 to present its regulatory filing plan​.  Full Article

Ani Pharma acquires Inderal XL and Innopran XL
Friday, 24 Feb 2017 

Ani Pharmaceuticals Inc : Ani pharmaceuticals acquires inderal® xl and innopran xl® . Ani pharmaceuticals inc - acquisitions were funded through a combination of cash and debt . Ani pharma - has begun selling inderal xl 80mg, 120mg sustained release capsules, innopran xl 80mg, 120mg sustained release capsules under current labels . Ani pharma - will transition inderal xl and innopran xl to ani label at a future date . Ani pharmaceuticals inc - acquired inderal xl from cranford pharmaceuticals, llc and innopran xl from holmdel pharmaceuticals lp .Ani pharmaceuticals inc- acquired inderal xl from cranford pharmaceuticals, llc and innopran xlfrom holmdel pharmaceuticals lp.  Full Article

ANI Pharmaceuticals Q2 adjusted earnings per share $1.11
Thursday, 4 Aug 2016 

ANI Pharmaceuticals : Reports record second quarter results and increases full year 2016 guidance . Q2 GAAP earnings per share $0.10 . Q2 earnings per share view $0.77 -- Thomson Reuters I/B/E/S . Q2 adjusted non-GAAP earnings per share $1.11 . Q2 revenue $31.3 million versus I/B/E/S view $27.6 million . Increases full year 2016 guidance . Sees full-year 2016 revenue $119 million to $134 million . Sees full-year 2016 adjusted non-GAAP earnings per share $4.00 to $4.25 .Full-year 2016 earnings per share view $3.63, revenue view $124.2 million -- Thomson Reuters I/B/E/S.  Full Article

ANI Pharmaceuticals announces FDA approval, launch of Nilutamide tablets
Monday, 18 Jul 2016 

ANI Pharmaceuticals Inc : ANI Pharmaceuticals announces FDA approval and immediate launch of Nilutamide tablets, the first generic competitor to Nilandron® .ANI will immediately launch product.  Full Article

ANI Pharmaceuticals announces FDA approval of oxcarbazepine tablets
Monday, 13 Jun 2016 

ANI Pharmaceuticals Inc : ANI Pharmaceuticals announces FDA approval of oxcarbazepine tablets .ANI Pharmaceuticals Inc says has received approval from FDA of prior approval supplement for oxcarbazepine tablets, 150mg, 300mg and 600mg.  Full Article

Aspen signs agreement with ANI Pharma for distribution of HPC injection in US
Tuesday, 17 May 2016 

Aspen Pharmacare Holdings Ltd : Agreement with ANI pharmaceuticals for distribution of hydroxyprogesterone caproate injection in US . Aspen Global Incorporated will be responsible for supplying HPC finished dose form .While ANI will be responsible for its marketing and distribution in US..  Full Article

ANI Pharmaceuticals enters credit facility for up to $30 mln
Friday, 13 May 2016 

Ani Pharmaceuticals Inc :Entered a new three year senior secured asset-based revolving credit facility for up to $30 million.  Full Article

ANI Pharmaceuticals Inc gives FY 2016 outlook
Thursday, 5 May 2016 

ANI Pharmaceuticals Inc:Expects FY 2016 net revenues to be between $119 million and $134 million.Expects FY 2016 adjusted non-GAAP EBITDA, to be between $55 million and $63 million.Expects FY 2016 adjusted non-GAAP net income per diluted share, to be between $3.54 and $3.91.Expects FY 2016 reported (US GAAP) diluted EPS to be between $0.30 and $0.65.  Full Article

ANI Pharmaceuticals Inc announces appointment of Stephen P. Carey as Vice President and Chief Financial Officer
Wednesday, 27 Apr 2016 

ANI Pharmaceuticals Inc:Says appointment of Stephen P. Carey to the position of Vice President and Chief Financial Officer, effective May 6, 2016.Steve replaces current CFO, Charlotte C. Arnold.  Full Article

ANI Pharmaceuticals Inc gives FY 2016 guidance
Tuesday, 23 Feb 2016 

ANI Pharmaceuticals Inc:Expects FY 2016 net revenues to be between $105 million and $120 million.Expects FY 2016 adjusted non-GAAP EBITDA to be between $45 million and $53 million.Expects FY 2016 adjusted non-GAAP net income per diluted share to be between $2.94 and $3.31.  Full Article

BRIEF-ANI Pharmaceuticals Q3 gaap earnings per share $0.40

* ANI Pharmaceuticals reports record third quarter and year-to-date 2017 results and narrows full year guidance